Format

Send to

Choose Destination
J Neurochem. 2009 Apr;109(2):502-12. doi: 10.1111/j.1471-4159.2009.05970.x. Epub 2009 Feb 7.

Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease.

Author information

1
Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York 10065, USA. mad2138@med.cornell.edu

Erratum in

  • J Neurochem. 2009 May;109(4):1192.. Nathan, Carl [added].

Abstract

Oxidative stress is one of the earliest events in the pathogenesis of Alzheimer's disease (AD) and can markedly exacerbate amyloid pathology. Modulation of antioxidant and anti-inflammatory pathways represents an important approach for AD therapy. Synthetic triterpenoids have been found to facilitate antioxidant response and reduce inflammation in several models. We investigated the effect of the triterpenoid, 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic acid-MethylAmide (CDDO-MA) in Tg19959 mice, which carry the human amyloid precursor protein with two mutations. These mice develop memory impairments and amyloid plaques as early as 2-3 months of age. CDDO-MA was provided with chow (800 mg/kg) from 1 to 4 months of age. CDDO-MA significantly improved spatial memory retention and reduced plaque burden, Abeta42 levels, microgliosis, and oxidative stress in Tg19959 mice.

PMID:
19200343
PMCID:
PMC3083825
DOI:
10.1111/j.1471-4159.2009.05970.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center